Skip to main content

Guardian Unlimited
Go to:  
SocietyGuardian.co.uk
Home Health Housing Regeneration Local government Voluntary sector Social care Talk
Jobs Careers Environment Conferences Books Big issues Comment Help

Mental health

  Search this site

 Recent articles
Time to set the record straight

Stay calm everyone, there's Prozac in the drinking water

Q&A: transsexualism

Schizophrenia drugs risk still unknown

Teenage clicks

Cut it out, please

Splendour in the grass

Q&A: self-harm

Interview: James Bellringer

Nick Johnstone: This Band-Aid won't stop the bleeding

Mental health  |  Social care

Doctors ordered to warn of antidepressant dangers

Tuesday July 27, 2004

Doctors will be required to warn all patients under 30 of the suicide risk posed by the antidepressant Seroxat following an investigation into the drug by a European medical agency, it emerged today.

The recommendation is expected to become law throughout the European Union (EU) in the autumn once the findings of the investigation are ratified by the European Commission.

The move responds to warnings about Seroxat made by the European Agency for the Evaluation of Medicinal Products (EMEA), which licenses drugs for use in the EU, in April.

The EMEA recommends that the antidepressant should be prescribed with extra caution to those aged between 18 and 29. It states that the drug can lead to an increased risk of "suicide-related behaviour in young adults", and calls for patients to be "monitored closely throughout treatment".

A significant number of patients prescribed Seroxat are under 30, according to the drug's manufacturer, GlaxoSmithKline.

The EMEA guidelines echo earlier warnings about the withdrawal symptoms experienced by patients on Seroxat, and backs the ban on prescribing the drug to those under 18, which came into force in the UK last year.

Mental health charity Mind called on the UK Medicines and Healthcare Regulatory Agency (MHRA) to order family doctors to warn all their depressed patients about the EMEA's findings immediately.

A Mind spokeswoman said: "The European ruling on Seroxat makes it very clear that the very real problems with this drug potentially go far beyond the groups already acknowledged to be at risk.

"When there are up to 800,000 people currently taking Seroxat in the UK, there is an urgent need for these risks to be made plainly known, and for GPs to be very aware of potential problems when they hand out prescriptions."

The MHRA launched its own investigation into Seroxat and other similar medicines, known selective serotonin re-uptake inhibitors, including Prozac, last year, but has yet to report its findings.


 Be in the know
Sign up for our email bulletins

 Related articles
19.06.2004: Glaxo changes tack after Spitzer assault
03.06.2004: Glaxo faces drug fraud lawsuit
14.06.2004: Safety alert on adult use of antidepressants
23.04.2004: SSRI dangers for children 'suppressed'

 Big issues
Mental health

 Glossary
A-Z guide to public services and voluntary sector speak

 Useful sites
European Agency for the Evaluation of Medicinal Products
Medicines and Healthcare Regulatory Agency
Mind
GlaxoSmithKline
The medicines and healthcare products regulatory agency
Department of Health: mental health
Depression Alliance
The Royal College of Psychiatrists
Institute of Psychiatry






Printable version | Send it to a friend | Save story



UP

SocietyGuardian.co.uk Guardian Newspapers Limited 2004